share_log

Granahan Investment Management LLC Increases Position in BioLife Solutions, Inc. (NASDAQ:BLFS)

Granahan Investment Management LLC Increases Position in BioLife Solutions, Inc. (NASDAQ:BLFS)

格兰纳汉投资管理公司增加在生物生命解决方案公司(纳斯达克市场代码：BLFS)的地位
Defense World ·  2022/09/10 04:51

Granahan Investment Management LLC lifted its holdings in BioLife Solutions, Inc. (NASDAQ:BLFS – Get Rating) by 40.3% during the first quarter, Holdings Channel.com reports. The institutional investor owned 609,604 shares of the medical equipment provider's stock after acquiring an additional 175,172 shares during the quarter. Granahan Investment Management LLC's holdings in BioLife Solutions were worth $13,856,000 as of its most recent filing with the Securities & Exchange Commission.

据Holdings Channel.com报道，Granahan Investment Management LLC在第一季度增持了生物生命解决方案公司(BLFS-GET Rating)40.3%的股份。该机构投资者在本季度额外收购了175,172股后，持有这家医疗设备提供商的609,604股股票。截至最近提交给证券交易委员会的文件，Granahan Investment Management LLC在BioLife Solutions持有的股份价值13,856,000美元。

A number of other hedge funds and other institutional investors have also recently modified their holdings of BLFS. Ranger Investment Management L.P. lifted its stake in BioLife Solutions by 43.0% in the fourth quarter. Ranger Investment Management L.P. now owns 1,255,260 shares of the medical equipment provider's stock valued at $46,784,000 after purchasing an additional 377,358 shares during the last quarter. Invesco Ltd. raised its holdings in BioLife Solutions by 26.9% during the 4th quarter. Invesco Ltd. now owns 769,736 shares of the medical equipment provider's stock valued at $28,688,000 after acquiring an additional 163,176 shares during the period. Barings LLC bought a new stake in BioLife Solutions during the 1st quarter valued at $2,076,000. JPMorgan Chase & Co. raised its holdings in BioLife Solutions by 20.9% during the 4th quarter. JPMorgan Chase & Co. now owns 471,575 shares of the medical equipment provider's stock valued at $17,576,000 after acquiring an additional 81,435 shares during the period. Finally, Nuveen Asset Management LLC raised its holdings in BioLife Solutions by 25.8% during the 4th quarter. Nuveen Asset Management LLC now owns 377,764 shares of the medical equipment provider's stock valued at $14,079,000 after acquiring an additional 77,364 shares during the period. Hedge funds and other institutional investors own 86.69% of the company's stock.

许多其他对冲基金和其他机构投资者最近也调整了对BLFS的持股。Ranger Investment Management L.P.在第四季度增持了BioLife Solutions 43.0%的股份。Ranger Investment Management L.P.在上个季度额外购买了377,358股票后，现在拥有这家医疗设备提供商1,255,260股票，价值46,784,000美元。景顺有限公司在第四季度增持了26.9%的BioLife Solutions股份。景顺公司目前持有这家医疗设备供应商的769,736股股票，价值28,688,000美元，在此期间又购入了163,176股。霸菱有限责任公司在第一季度购买了BioLife Solutions的新股份，价值2,076,000美元。摩根大通在第四季度增持了BioLife Solutions的股份20.9%。摩根大通(JPMorgan Chase&Co.)在此期间增持了81,435股，目前持有这家医疗设备供应商471,575股，价值17,576,000美元。最后，Nuveen Asset Management LLC在第四季度将其在BioLife Solutions的持股增加了25.8%。Nuveen Asset Management LLC在此期间额外收购了77,364股票，目前拥有这家医疗设备提供商377,764股票，价值14,079,000美元。对冲基金和其他机构投资者持有该公司86.69%的股票。

Get
到达
BioLife Solutions
生物生命解决方案
alerts:
警报：

BioLife Solutions Trading Down 0.3 %

BioLife Solutions股价下跌0.3%

BioLife Solutions stock opened at $26.62 on Friday. The stock has a market cap of $1.13 billion, a P/E ratio of -11.83 and a beta of 1.91. BioLife Solutions, Inc. has a fifty-two week low of $10.40 and a fifty-two week high of $58.80. The firm's fifty day moving average price is $20.70 and its 200-day moving average price is $18.39. The company has a debt-to-equity ratio of 0.02, a quick ratio of 2.54 and a current ratio of 3.55.

BioLife Solutions的股票周五开盘报26.62美元。该股市值为11.3亿美元，市盈率为-11.83，贝塔系数为1.91。BioLife Solutions，Inc.的股价为52周低点10.40美元，52周高点为58.80美元。该公司的50日移动均线价格为20.70美元，200日移动均线价格为18.39美元。该公司的负债权益比为0.02，速动比率为2.54，流动比率为3.55。

Insider Transactions at BioLife Solutions

BioLife Solutions的内幕交易

In other news, CRO Marcus Schulz sold 4,600 shares of the company's stock in a transaction on Wednesday, August 3rd. The shares were sold at an average price of $20.03, for a total value of $92,138.00. Following the transaction, the executive now owns 36,218 shares of the company's stock, valued at $725,446.54. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. In other BioLife Solutions news, COO Greef Roderick De sold 9,158 shares of the company's stock in a transaction dated Tuesday, July 12th. The shares were sold at an average price of $15.79, for a total transaction of $144,604.82. Following the completion of the sale, the chief operating officer now directly owns 124,458 shares in the company, valued at $1,965,191.82. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, CRO Marcus Schulz sold 4,600 shares of the company's stock in a transaction dated Wednesday, August 3rd. The shares were sold at an average price of $20.03, for a total transaction of $92,138.00. Following the sale, the executive now owns 36,218 shares of the company's stock, valued at $725,446.54. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 18,401 shares of company stock valued at $313,764. 3.30% of the stock is currently owned by company insiders.
在其他新闻方面，CRO马库斯·舒尔茨在8月3日星期三的一笔交易中出售了4600股该公司股票。这些股票的平均价格为20.03美元，总价值为92,138.00美元。交易完成后，这位高管现在持有该公司36,218股股票，价值725,446.54美元。这笔交易是在提交给美国证券交易委员会的一份法律文件中披露的，该文件可在美国证券交易委员会网站上查阅。在BioLife Solutions的其他消息中，首席运营官格里夫·罗德里克·德在7月12日(星期二)的交易中出售了9158股该公司股票。这些股票以15.79美元的平均价格出售，总成交金额为144,604.82美元。出售完成后，首席运营官现在直接拥有该公司124,458股，价值1,965,191.82美元。这笔交易是在提交给美国证券交易委员会的一份文件中披露的，可以通过这个链接访问。此外，CRO马库斯·舒尔茨在日期为8月3日(星期三)的交易中出售了4600股该公司股票。这些股票以20.03美元的平均价格出售，总成交金额为92,138.00美元。出售后，这位高管现在持有该公司36,218股股票，价值725,446.54美元。此次拍卖的披露信息可在此处找到。在上个季度，内部人士出售了18,401股公司股票，价值313,764美元。3.30%的股份目前由公司内部人士持有。

Wall Street Analysts Forecast Growth

华尔街分析师预测经济增长

BLFS has been the topic of a number of analyst reports. B. Riley lowered their target price on shares of BioLife Solutions from $48.00 to $34.00 in a report on Tuesday, May 17th. Cowen lowered their target price on shares of BioLife Solutions to $29.00 in a report on Monday, August 15th. One equities research analyst has rated the stock with a sell rating and three have assigned a buy rating to the stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $31.25.

BLFS一直是许多分析师报告的主题。B.莱利在5月17日星期二的一份报告中将BioLife Solutions的目标价从48.00美元下调至34.00美元。考恩在8月15日星期一的一份报告中将BioLife Solutions的目标价下调至29.00美元。一位股票研究分析师将该股的评级定为卖出，三位分析师将其评级定为买入。根据MarketBeat的数据，该公司的平均评级为“中等买入”，平均目标价为31.25美元。

BioLife Solutions Company Profile

BioLife Solutions公司简介

(Get Rating)

(获取评级)

BioLife Solutions, Inc develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.

BioLife Solutions，Inc.为美国、加拿大、欧洲、中东、非洲和国际上的细胞和基因治疗行业开发、制造和提供生物生产工具和服务。该公司的产品用于基础和应用研究，以及基于生物的疗法的商业制造。

Further Reading

进一步阅读

  • Get a free copy of the StockNews.com research report on BioLife Solutions (BLFS)
  • MarketBeat: Week in Review 9/5 – 9/9
  • Prepare For A Record-Setting Quarter For Cyber Security Stocks
  • The Auto Market Is Slowly Recovering, These Stocks May Outperform
  • Is DocuSign On The Verge Of A Major Reversal?
  • Oil and Gas Stocks: A Safe Way to Invest in Renewable Energy
  • 免费获取StockNews.com关于BioLife解决方案的研究报告(BLFS)
  • MarketBeat：回顾一周9/5-9/9
  • 为网络安全股创纪录的季度做准备
  • 汽车市场正在缓慢复苏，这些股票可能表现优异
  • DocuSign是否即将发生重大逆转？
  • 石油和天然气股票：投资可再生能源的安全途径

Want to see what other hedge funds are holding BLFS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioLife Solutions, Inc. (NASDAQ:BLFS – Get Rating).

想看看还有哪些对冲基金持有BLFS吗？访问HoldingsChannel.com获取BioLife Solutions，Inc.(纳斯达克代码：BLFS-GET Rating)的最新13F备案文件和内幕交易信息。

Receive News & Ratings for BioLife Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLife Solutions and related companies with MarketBeat.com's FREE daily email newsletter.

每日收到有关BioLife解决方案的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对BioLife Solutions和相关公司的最新新闻和分析师评级的每日简要摘要。

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发